Displaying drugs 51 - 75 of 190 in total
Loncastuximab tesirine
Relapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL) are a therapeutic challenge for patients who have undergone prior systemic therapies with limited success. Prognosis is poor and more effective therapies are needed to treat relapsed/refractory cases and improve survival. On April 23 2021, the Food and Drug Administration granted accelerated...
Approved
Investigational
Matched Synonyms: … A protease cleavable valine-alanine linker ... Humanized monoclonal immunoglobulin G1 antibody directed against human CD19 conjugated to SG3199 through …
Matched Description: … Relapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL) are a therapeutic challenge for patients ... refractory B-cell lymphoma is based on promising results from the LOTIS-2 clinical trial. ... and improve survival. …
Matched Categories: … Heterocyclic Compounds, 2-Ring ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES ... P-glycoprotein substrates …
Matched Description: … Relapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL) are a therapeutic challenge for patients ... refractory B-cell lymphoma is based on promising results from the LOTIS-2 clinical trial. ... and improve survival. …
Matched Categories: … Heterocyclic Compounds, 2-Ring ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES ... P-glycoprotein substrates …
Brentuximab vedotin
Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the...
Approved
Investigational
Matched Synonyms: … Moab, chimeric, SGN-30, to CD30 antigen …
Matched Description: … In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph ... [L1737] The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy ... Most individuals with Hodgkin's lymphoma have the classical type. …
Matched Categories: … P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Products: … ADCETRIS 50 MG IV INFÜZYONLUK ÇÖZELTI KONSANTRESI IÇIN TOZ IÇEREN FLAKON ,FLAKON, 1 ADET …
Matched Description: … In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph ... [L1737] The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy ... Most individuals with Hodgkin's lymphoma have the classical type. …
Matched Categories: … P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Products: … ADCETRIS 50 MG IV INFÜZYONLUK ÇÖZELTI KONSANTRESI IÇIN TOZ IÇEREN FLAKON ,FLAKON, 1 ADET …
Glatiramer
Glatiramer acetate is a mix of synthetic polypeptides that includes L-glutamic acid, L-alanine, L-tyrosine, and L-lysine at an average molar fraction of 0.141, 0.427, 0.095, and 0.338, respectively. Since glatiramer acetate is a heterogeneous drug, there is limited information about its physicochemical properties. Originally, glatiramer acetate was designed as a...
Approved
Investigational
Matched Synonyms: … (T,G)-A-L ... COP 1 ... COP-1 …
Matched Description: … [A248870] Along with [human interferon beta], [teriflunomide], and [dimethyl fumarate], glatiramer acetate ... [A248880] It was approved by the FDA in 1996, and a generic version became available in 2017. ... myelin antigen involved in the development of multiple sclerosis (MS), to induce experimental autoimmune …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Matched Description: … [A248870] Along with [human interferon beta], [teriflunomide], and [dimethyl fumarate], glatiramer acetate ... [A248880] It was approved by the FDA in 1996, and a generic version became available in 2017. ... myelin antigen involved in the development of multiple sclerosis (MS), to induce experimental autoimmune …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Pirtobrutinib
Pirtobrutinib is a small molecule and a highly selective non-covalent inhibitor of Bruton’s tyrosine kinase (BTK). Its high selectivity has been associated with lower discontinuation rates due to adverse events and a lower incidence of atrial fibrillation. Unlike BTK covalent inhibitors, such as ibrutinib, that bind to the cysteine 481...
Approved
Investigational
Matched Synonyms: … (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole ... 1h-pyrazole-4-carboxamide, 5-amino-3-(4-(((5-fluoro-2-methoxybenzoyl)amino)methyl)phenyl)-1-((1s)-2,2,2 ... 5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-((2s)-1,1,1-trifluoropropan-2-yl)-1h-pyrazole …
Matched Iupac: … 5-amino-3-(4-{[(5-fluoro-2-methoxyphenyl)formamido]methyl}phenyl)-1-[(2S)-1,1,1-trifluoropropan-2-yl] ... -1H-pyrazole-4-carboxamide …
Matched Description: … Pirtobrutinib is a small molecule and a highly selective non-covalent inhibitor of Bruton’s tyrosine ... Its high selectivity has been associated with lower discontinuation rates due to adverse events and a …
Matched Categories: … Heterocyclic Compounds, 1-Ring ... Antineoplastic and Immunomodulating Agents ... P-glycoprotein inhibitors ... P-glycoprotein substrates ... Cytochrome P-450 Substrates …
Matched Iupac: … 5-amino-3-(4-{[(5-fluoro-2-methoxyphenyl)formamido]methyl}phenyl)-1-[(2S)-1,1,1-trifluoropropan-2-yl] ... -1H-pyrazole-4-carboxamide …
Matched Description: … Pirtobrutinib is a small molecule and a highly selective non-covalent inhibitor of Bruton’s tyrosine ... Its high selectivity has been associated with lower discontinuation rates due to adverse events and a …
Matched Categories: … Heterocyclic Compounds, 1-Ring ... Antineoplastic and Immunomodulating Agents ... P-glycoprotein inhibitors ... P-glycoprotein substrates ... Cytochrome P-450 Substrates …
Hydroxychloroquine
Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like chloroquine. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxychloroquine is also used for the prophylaxis of malaria in...
Approved
Matched Synonyms: … 7-chloro-4-[5-(N-ethyl-N-2-hydroxyethylamino)-2-pentyl]aminoquinoline ... 7-chloro-4-(4-(ethyl(2-hydroxyethyl)amino)-1-methylbutylamino)quinoline ... 7-chloro-4-(4-(N-ethyl-N-β-hydroxyethylamino)-1-methylbutylamino)quinoline …
Matched Iupac: … 2-({4-[(7-chloroquinolin-4-yl)amino]pentyl}(ethyl)amino)ethan-1-ol …
Matched Description: … -2. ... Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. ... [L8072] A recent study reported a fatality in the group being treated with hydroxychloroquine for …
Matched Salts cas: … 747-36-4 …
Matched Categories: … Heterocyclic Compounds, 2-Ring ... Antiparasitic Products, Insecticides and Repellents ... P-glycoprotein inhibitors ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2C8 Substrates …
Matched Iupac: … 2-({4-[(7-chloroquinolin-4-yl)amino]pentyl}(ethyl)amino)ethan-1-ol …
Matched Description: … -2. ... Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. ... [L8072] A recent study reported a fatality in the group being treated with hydroxychloroquine for …
Matched Salts cas: … 747-36-4 …
Matched Categories: … Heterocyclic Compounds, 2-Ring ... Antiparasitic Products, Insecticides and Repellents ... P-glycoprotein inhibitors ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2C8 Substrates …
Abiraterone
Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 2011, respectively. It is used to treat metastatic...
Approved
Matched Synonyms: … (3β)-17-(pyridin-3-yl)androsta-5,16-dien-3-ol ... 17-(3-Pyridyl)androsta-5,16-dien-3beta-ol …
Matched Iupac: … 11aH-cyclopenta[a]phenanthren-7-ol ... (3aS,3bR,7S,9aR,9bS,11aS)-9a,11a-dimethyl-1-(pyridin-3-yl)-3H,3aH,3bH,4H,6H,7H,8H,9H,9aH,9bH,10H,11H, …
Matched Description: … Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17 ... ] and September 2011,[A260880] respectively. ... [L40968, L40193, L47740, L47745] As abiraterone has poor oral bioavailability and is susceptible to …
Matched Salts cas: … 154229-18-2 …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Hormone Antagonists and Related Agents ... Metabolic Side Effects of Drugs and Substances ... Hormones, Hormone Substitutes, and Hormone Antagonists ... P-glycoprotein inhibitors …
Matched Iupac: … 11aH-cyclopenta[a]phenanthren-7-ol ... (3aS,3bR,7S,9aR,9bS,11aS)-9a,11a-dimethyl-1-(pyridin-3-yl)-3H,3aH,3bH,4H,6H,7H,8H,9H,9aH,9bH,10H,11H, …
Matched Description: … Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17 ... ] and September 2011,[A260880] respectively. ... [L40968, L40193, L47740, L47745] As abiraterone has poor oral bioavailability and is susceptible to …
Matched Salts cas: … 154229-18-2 …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Hormone Antagonists and Related Agents ... Metabolic Side Effects of Drugs and Substances ... Hormones, Hormone Substitutes, and Hormone Antagonists ... P-glycoprotein inhibitors …
Galactose
Galactose has been used in trials studying the treatment and diagnosis of Hepatitis C, Hepatic Cancer, Wilsons Disease, Diabetic Macular Oedema, and Focal Segmental Glomerulosclerosis, among others. There are even proposals for its use in accelerating senescence in mice, rats, and Drosophila, for its association with ovarian cancer, or even...
Approved
Investigational
Matched Description: … Regardless, although it is predominantly used as a pathway to generate glucose fuel for the human body ... As a naturally occurring sugar, it may be found in a number dairy products. ... Galactose has been used in trials studying the treatment and diagnosis of Hepatitis C, Hepatic Cancer …
Montelukast
Montelukast was first approved for clinical use by the US FDA in 1998 as Merck's brand name Singulair. The medication is a member of the leukotriene receptor antagonist (LTRA) category of drugs.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] Although capable of demonstrating effectiveness, the use of such LTRAs like montelukast is typically in addition to or...
Approved
Matched Synonyms: … (R-(E))-1-(((1-(3-(2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl ... 1-[[[(1 R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl] phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl] …
Matched Iupac: … 2-[1-({[(1R)-1-{3-[(1E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl …
Matched Description: … has since become available as a generic and as a brand name product. ... [L6301] The medication is a member of the leukotriene receptor antagonist (LTRA) category of drugs. ... montelukast to elicit neuropsychiatric effects like agitation, hallucinations, suicidal behaviour, and …
Matched Salts cas: … 151767-02-1 …
Matched Mixtures name: … VALTROVER G ... VALTROVER G ... LEVMONT 2.5/4 MG CIGNEME TABLET, 90 ADET …
Matched Categories: … Heterocyclic Compounds, 2-Ring ... Hormones, Hormone Substitutes, and Hormone Antagonists ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP1A2 Inducers ... Cytochrome P-450 CYP2A6 Substrates …
Matched Products: … MONK-P ... Spirant 5 Chewable (Montelukast sodium tablets 5 mg) ... MONAST 5 (Montelukast Paediatric Chewable Tablets 5 mg) …
Matched Iupac: … 2-[1-({[(1R)-1-{3-[(1E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl …
Matched Description: … has since become available as a generic and as a brand name product. ... [L6301] The medication is a member of the leukotriene receptor antagonist (LTRA) category of drugs. ... montelukast to elicit neuropsychiatric effects like agitation, hallucinations, suicidal behaviour, and …
Matched Salts cas: … 151767-02-1 …
Matched Mixtures name: … VALTROVER G ... VALTROVER G ... LEVMONT 2.5/4 MG CIGNEME TABLET, 90 ADET …
Matched Categories: … Heterocyclic Compounds, 2-Ring ... Hormones, Hormone Substitutes, and Hormone Antagonists ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP1A2 Inducers ... Cytochrome P-450 CYP2A6 Substrates …
Matched Products: … MONK-P ... Spirant 5 Chewable (Montelukast sodium tablets 5 mg) ... MONAST 5 (Montelukast Paediatric Chewable Tablets 5 mg) …
Mitoxantrone
An anthracenedione-derived antineoplastic agent.
Approved
Investigational
Matched Synonyms: … 1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone …
Matched Iupac: … 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)-9,10-dihydroanthracene-9,10-dione …
Matched Salts cas: … 70476-82-3 …
Matched Categories: … P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index ... Anthracyclines and Related Substances ... Antineoplastic and Immunomodulating Agents ... Cytotoxic Antibiotics and Related Substances …
Matched Products: … MİTOXANTRON EBEWE 10 MG/5 ML IV İNFÜZYON İÇİN KONSANTRE ÇÖZELTİ İÇEREN FLAKON, 1 ADET ... MITOXANTRONE BAXTER INJECTION 2 mg/ml ... MİTOXANTRONE BAXTER 20 MG/10 ML ENJEKSİYONLUK ÇÖZELTİ, 1 ADET …
Matched Iupac: … 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)-9,10-dihydroanthracene-9,10-dione …
Matched Salts cas: … 70476-82-3 …
Matched Categories: … P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index ... Anthracyclines and Related Substances ... Antineoplastic and Immunomodulating Agents ... Cytotoxic Antibiotics and Related Substances …
Matched Products: … MİTOXANTRON EBEWE 10 MG/5 ML IV İNFÜZYON İÇİN KONSANTRE ÇÖZELTİ İÇEREN FLAKON, 1 ADET ... MITOXANTRONE BAXTER INJECTION 2 mg/ml ... MİTOXANTRONE BAXTER 20 MG/10 ML ENJEKSİYONLUK ÇÖZELTİ, 1 ADET …
Teplizumab
Teplizumab (teplizumab-mzwv) is a humanized IgG1 kappa CD3-directed monoclonal antibody used to delay the onset of type 1 diabetes (T1D).[A241480,A241045,A241475,L44091] T1D is an autoimmune condition in which T cell-mediated destruction of pancreatic β cells leads to loss of insulin production, impaired glycemic control, and reliance on exogenous insulin. Anti-CD3 therapy...
Approved
Investigational
Matched Description: … the onset of type 1 diabetes (T1D). ... 1 diabetes. ... Teplizumab (teplizumab-mzwv) is a humanized IgG1 kappa CD3-directed monoclonal antibody used to delay …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Belatacept
Belatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it...
Approved
Investigational
Matched Description: … antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin ... and it is a homodimer of two homologous polypeptide chains of 357 amino acids each. ... Belatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Alefacept
Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD.
Approved
Investigational
Withdrawn
Matched Description: … leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human ... Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human …
Matched Categories: … CD2-directed LFA-3/Fc Fusion Protein ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Matched Categories: … CD2-directed LFA-3/Fc Fusion Protein ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Lutetium Lu-177 vipivotide tetraxetan
Lutetium Lu-177 vipivotide tetraxetan is a radioligand therapeutic agent. It consists of a radionuclide, lutetium Lu-177, linked to a moiety that binds to PSMA, a transmembrane protein that is expressed in prostate cancer. Lutetium Lu-177 vipivotide tetraxetan was first approved by the FDA on March 23, 2022 as a treatment...
Approved
Matched Iupac: … (177Lu)lutetium(3+) 2-[4,7-bis(carboxylatomethyl)-10-[({[(1r,4r)-4-{[(1S)-1-{[(5S)-5-carboxy-5-({[(1S ... ]methyl}carbamoyl)methyl]-1,4,7,10-tetraazacyclododecan-1-yl]acetate ... )-1,3-dicarboxypropyl]carbamoyl}amino)pentyl]carbamoyl}-2-(naphthalen-2-yl)ethyl]carbamoyl}cyclohexyl …
Matched Description: … [L41290] In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended ... treatment for prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer ... It consists of a radionuclide, [lutetium Lu-177], linked to a moiety that binds to PSMA, a transmembrane …
Matched Categories: … Compounds used in a research, industrial, or household setting …
Matched Products: … 1 Pluvicto …
Matched Description: … [L41290] In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended ... treatment for prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer ... It consists of a radionuclide, [lutetium Lu-177], linked to a moiety that binds to PSMA, a transmembrane …
Matched Categories: … Compounds used in a research, industrial, or household setting …
Matched Products: … 1 Pluvicto …
Capromab pendetide
Capromab is a Murine IgG1 monoclonal 7E11-C5.3 antibody that recognizes prostate specific membrane antigen (PSMA – also known as glutamate carboxypeptidase 2) from prostate cancer cells and normal prostate tissue. When linked to pendetide, capromab is used as a chelating agent for the radionuclide Indium In-111 during imaging to evaluate...
Approved
Matched Description: … (PSMA – also known as glutamate carboxypeptidase 2) from prostate cancer cells and normal prostate tissue ... Capromab is a Murine IgG1 monoclonal 7E11-C5.3 antibody that recognizes prostate specific membrane antigen ... When linked to pendetide, capromab is used as a chelating agent for the radionuclide [Indium In-111] …
Matched Categories: … Compounds used in a research, industrial, or household setting ... Indicators and Reagents ... Amino Acids, Peptides, and Proteins …
Matched Categories: … Compounds used in a research, industrial, or household setting ... Indicators and Reagents ... Amino Acids, Peptides, and Proteins …
Relatlimab
Relatlimab is a human IgG4 monoclonal antibody and novel immune checkpoint inhibitor that targets lymphocyte activation gene-3 (LAG-3).[A246165,L41265] It was the first commercially developed anti-LAG-3 antibody, entering clinical trials in 2013, and has garnered interest in the treatment of a variety of cancers, including leukemia and melanoma. As immune checkpoint...
Approved
Investigational
Matched Description: … Relatlimab is a human IgG4 monoclonal antibody and novel immune checkpoint inhibitor that targets lymphocyte ... [L41265,L41300] It was the first anti-LAG-3 antibody to demonstrate benefit in a Phase 3 study, as well ... in 2013,[A246155] and has garnered interest in the treatment of a variety of cancers, including leukemia …
Matched Categories: … Lymphocyte Activation Gene-3 Blocker ... nivolumab and relatlimab ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Matched Categories: … Lymphocyte Activation Gene-3 Blocker ... nivolumab and relatlimab ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Janssen COVID-19 Vaccine
The Janssen COVID-19 vaccine (Ad26.COV2.S) is a recombinant vaccine that contains an adenovirus serotype 26 (Ad26) vector expressing a stabilized SARS-CoV-2 spike protein. The vaccine was created in collaboration with Johnson and Johnson (J&J), Janssen Pharmaceutical, and the Beth Israel Deaconess Medical Center. A preclinical study in hamsters infected with...
Approved
Investigational
Matched Description: … As of June 2020, a Phase 1/2 clinical trial in adult humans was announced to evaluate the safety, immunogenicity ... 26 (Ad26) vector expressing a stabilized SARS-CoV-2 spike protein. ... A preclinical study in hamsters infected with SARS-COV-2 infection[A220053] showed a single immunization …
Tositumomab
Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine).
Approved
Investigational
Matched Description: … Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda ... It can be covalently linked to Iodine 131 (a radioactive isotope of iodine). …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Andusomeran
Andusomeran is a COVID-19 mRNA vaccine developed for use during the 2023-2024 season.[L40074,L48832,L48837] It is similar to previous mRNA vaccines developed by Moderna (e.g. elasomeran, imelasomeran), but is designed to be effective against the Omicron XBB.1.5 subvariant.
Approved
Matched Description: … Andusomeran is a COVID-19 mRNA vaccine developed for use during the 2023-2024 season. …
Fomivirsen
Fomivirsen is a antisense 21 mer phosphorothioate oligonucleotide. It is an antiviral agent that was used in the treatment of cytomegalovirus retinitis (CMV) in immunocompromised patients, including those with AIDS. As a complementary nucleotide to the messenger RNA of the major immediate-early region proteins of human cytomegalovirus, it disrupts the...
Approved
Investigational
Withdrawn
Matched Description: … As a complementary nucleotide to the messenger RNA of the major immediate-early region proteins of human ... Fomivirsen is a antisense 21 mer phosphorothioate oligonucleotide. ... The drug was withdrawn by the FDA because while there was a high unmet need for drugs to treat CMV when …
Matched Salts cas: … 160369-77-7 …
Matched Categories: … Nucleic Acids, Nucleotides, and Nucleosides ... Compounds used in a research, industrial, or household setting …
Matched Salts cas: … 160369-77-7 …
Matched Categories: … Nucleic Acids, Nucleotides, and Nucleosides ... Compounds used in a research, industrial, or household setting …
Tuberculin purified protein derivative
Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with Mycobacterium tuberculosis...
Approved
Matched Description: … The purified protein fraction is isolated from culture media filtrates of a human strain of Mycobacterium ... minimize the risk of transmission of infection with *Mycobacterium tuberculosis* through early diagnosis and ... Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction …
Matched Categories: … Skin Test Antigen ... Compounds used in a research, industrial, or household setting ... Indicators and Reagents ... Amino Acids, Peptides, and Proteins …
Matched Products: … PPD TÜBERKÜLİN 100 TU/2 ML İNTRADERMAL ENJEKSİYONLUK ÇÖZELTİ, 1 ADET ... PPD TÜBERKÜLIN 5 TU/ 0.1 ML INTRADERMAL ENJEKSIYONLUK ÇÖZELTI IÇEREN FLAKON, 1 ADET ... BIOCINE TESTPPD 5-UI/ 01 ML …
Matched Categories: … Skin Test Antigen ... Compounds used in a research, industrial, or household setting ... Indicators and Reagents ... Amino Acids, Peptides, and Proteins …
Matched Products: … PPD TÜBERKÜLİN 100 TU/2 ML İNTRADERMAL ENJEKSİYONLUK ÇÖZELTİ, 1 ADET ... PPD TÜBERKÜLIN 5 TU/ 0.1 ML INTRADERMAL ENJEKSIYONLUK ÇÖZELTI IÇEREN FLAKON, 1 ADET ... BIOCINE TESTPPD 5-UI/ 01 ML …
Tozinameran
The Pfizer-BioNTech COVID-19 vaccine (also known as BNT162b2, Tozinameran, and Comirnaty), is one of four advanced mRNA-based vaccines developed through "Project Lightspeed," a joint program between Pfizer and BioNTech.[L15002,L15007,L36025] Comirnaty is a nucleoside modified mRNA (modRNA) vaccine encoding an optimized full-length version of the severe acute respiratory syndrome coronavirus 2...
Approved
Investigational
Matched Description: … [A225386] Comirnaty was granted a EUA in the UK on December 2, 2020,[L26676] and in Canada on December ... a similar safety profile to other viral vaccines over a span of approximately 2 months. ... Comirnaty is also approved for use as a fourth booster shot in adults 50 years of age and older. …
Matched Mixtures name: … Comirnaty Original & Omicron Ba.4/ba.5 ... Comirnaty Original & Omicron Ba.4/ba.5 ... Comirnaty Original & Omicron Ba.4/ba.5 …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Matched Mixtures name: … Comirnaty Original & Omicron Ba.4/ba.5 ... Comirnaty Original & Omicron Ba.4/ba.5 ... Comirnaty Original & Omicron Ba.4/ba.5 …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Besilesomab
Besilesomab is a mouse monoclonal antibody labelled with the radioactive isotope technetium-99m for determining the location of inflammation/infection in peripheral bone in adults with suspected osteomyelitis [FDA Label]. Utilised only as a diagnostic agent, besilesomab is currently approved by the EMEA for marketing and use in various European countries like...
Approved
Matched Description: … Utilised only as a diagnostic agent, besilesomab is currently approved by the EMEA for marketing and ... Besilesomab is a mouse monoclonal antibody labelled with the radioactive isotope technetium-99m for determining ... various European countries like Italy, France, Germany, Spain, Portugal, Norway, Sweden, the Netherlands, and …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Cemiplimab
Cemiplimab is a fully human monoclonal antibody that works against programmed death receptor-1 (PD-1), which is a negative regulator of T cell function. By blocking PD-1, cemiplimab works to enhance T cell-mediated antitumour responses. Cemiplimab was first approved by the FDA on September 28, 2018, as the first FDA-approved treatment...
Approved
Investigational
Matched Description: … Cemiplimab is a fully human monoclonal antibody that works against programmed death receptor-1 (PD-1) ... , which is a negative regulator of T cell function. ... [A39201,A254177,L4615] It was later approved to be used in basal cell carcinoma and non-small non-small …
Matched Categories: … Amino Acids, Peptides, and Proteins ... PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES ... Programmed Death Receptor-1 Blocking Antibody …
Matched Categories: … Amino Acids, Peptides, and Proteins ... PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES ... Programmed Death Receptor-1 Blocking Antibody …
Imlifidase
Chronic kidney disease (CKD) is a progressive and irreversible disease that represents a significant burden for both the individual and healthcare system at large. Currently available treatments for end-stage renal disease are limited to dialysis and renal transplantation, with the former associated with significant costs and lower quality of life.[A225836,A225916]...
Approved
Investigational
Matched Description: … such as CDC and ADCC by cleaving the heavy chains of human immunoglobulin G (IgG) antibodies. ... [A225836,A225916]
Patients who have developed human leukocyte antigen (HLA) sensitization from prior ... Chronic kidney disease (CKD) is a progressive and irreversible disease that represents a significant …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Pitavastatin
Pitavastatin, also known as the brand name product Livalo, is a lipid-lowering drug belonging to the statin class of medications. By inhibiting the endogenous production of cholesterol within the liver, statins lower abnormal cholesterol and lipid levels and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competitively...
Approved
Matched Iupac: … (3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid …
Matched Description: … for people with a moderate to high risk of development of CVD, such as those with Type 2 Diabetes. ... (heart attack, stroke, coronary revascularization, and coronary death) for every 1 mmol/L reduction ... event occurring within 5 years) statins cause a 20%-22% relative reduction in major cardiovascular events …
Matched Salts cas: … 147526-32-7 ... 956116-90-8 ... 574705-92-3 …
Matched Categories: … Heterocyclic Compounds, 2-Ring ... Cytochrome P-450 Substrates ... P-glycoprotein substrates ... Cytochrome P-450 CYP2C8 Substrates ... Cytochrome P-450 CYP2C9 Substrates …
Matched Products: … Trolise 4 mg Filmtabletten ... Trolise 1 mg Filmtabletten ... ALIPZA 4 MG FILM KAPLI TABLET, 90 ADET …
Matched Description: … for people with a moderate to high risk of development of CVD, such as those with Type 2 Diabetes. ... (heart attack, stroke, coronary revascularization, and coronary death) for every 1 mmol/L reduction ... event occurring within 5 years) statins cause a 20%-22% relative reduction in major cardiovascular events …
Matched Salts cas: … 147526-32-7 ... 956116-90-8 ... 574705-92-3 …
Matched Categories: … Heterocyclic Compounds, 2-Ring ... Cytochrome P-450 Substrates ... P-glycoprotein substrates ... Cytochrome P-450 CYP2C8 Substrates ... Cytochrome P-450 CYP2C9 Substrates …
Matched Products: … Trolise 4 mg Filmtabletten ... Trolise 1 mg Filmtabletten ... ALIPZA 4 MG FILM KAPLI TABLET, 90 ADET …
Displaying drugs 51 - 75 of 190 in total